Phio Pharmaceuticals price to sales ratio PHIO

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 49.4×; Mar 2020
Peer median: 0.9×

Phio Pharmaceuticals' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Mar 2020, at 49.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	49.4×	46.2×	170×
2019	184×	40.5×	184×
2018	36.8×	35.0×	43.9×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	81.6×	78.6×	171×
2013	81.2×	81.2×	120×

Against its peers

Companies in Drug Manufacturers - General nearest Phio Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
PHIOPhio Pharmaceuticals	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Phio Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.